|[February 27, 2013]
IGI Laboratories to Present at 25th Annual ROTH Capital Conference on March 20, 2013
BUENA, N.J. --(Business Wire)--
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical
generic drug development and manufacturing company, will be presenting
at the 25th Annual ROTH Conference. The Conference will take place on
March 17-20, 2013 at the Ritz-Carlton in Dana Point, California.
Jason Grenfell-Gardner, CEO and President and Jenniffer Collins, Chief
Financial Officer of IGI Laboratories, Inc. will present on Wednesday
March 20, 2013 at 9:00 a.m. PT / 12:00 p.m. ET. Investors attending the
conferences who wish to meet with Mr. Grenfell-Gardner and Mrs. Collins
for a one-on-one meeting should contact their ROTH Capital
The presentation will be webcast and will be accessible online on the
Investors section of the Company's website at http://www.igilabs.com.
A replay will be available for 90 days.
About IGI Laboratories, Inc.
IGI Laboratories is a developer and manufacturer of topical formulations
for the pharmaceutical, OTC, and cosmetic markets. Our mission is to be
a leading player in the generic topical prescription drug market.
IGI Laboratories, Inc. "Safe Harbor" Statement under the Private
Securities Litigation Reform Act of 1995. This press release includes
certain "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, plans, objectives,
expectations and intentions, and other statements contained in this
press release that are not historical facts and statements identified by
words such as " will," "possible," "one time," "provides an
opportunity," "continue" or words of similar meaning. These statements
are based on our current beliefs or expectations and are inherently
subject to various risks and uncertainties, including those set forth
under the caption "Risk Factors" in IGI Laboratories, Inc.'s most recent
Annual Report on Form 10-K and Quarterly Reports on Form 10-Q as filed
with the Securities and Exchange Commission. Actual results may differ
materially from these expectations due to changes in global political,
economic, business, competitive, market and regulatory factors or IGI
Laboratories, Inc.'s ability to implement business strategies. IGI
Laboratories, Inc. does not undertake any obligation to update any
forward-looking statements contained in this document as a result of new
information, future events or otherwise.
[ Back To TMCnet.com's Homepage ]